Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0382 versus placebo and liraglutide for hepatic glycogen metabolism in overweight or obese adults with type 2 diabetes
NL-OMON50158Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cotadutide in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by AstraZeneca. Primary endpoints: Change in hepatic glycogen concentration adjusted for liver volume and Percentage change in fasting hepatic glycogen concentration adjusted for liver volume. Started Jan 2020; status: active, not recruiting.
02
Drugs
cotadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NL-OMON50158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50158.